Conditions: Acute Myeloid Leukemia
Allocation: RANDOMIZED | Intervention model: PARALLEL
Enrollment: 152
Healthy volunteers: no

Brief summary:
Double-Blind Placebo-Controlled Randomized Phase 2 Study evaluating the efficacy of lirilumab (IPH2102/BMS-986015) as Maintenance Treatment administered in elderly patients with Acute Myeloid Leukemia (AML) in first complete remission

Detailed description:

Arms:
arm 1: lirilumab (IPH2102/BMS986015) at 1 mg/kg arm 2: lirilumab (IPH2102/BMS986015) at 0.1 mg/kg arm 3: Normal saline solution

Interventions: intervention 1: IPH2102 at 0.1 mg/kg intervention 2: IPH2102 at 1 mg/kg intervention 3: Placebo (normal saline solution)
Intervention descriptions: intervention 1: every 3 months intervention 2: every 4 weeks intervention 3: every 4 weeks

Protocol document: